What Researchers Did
Researchers conducted a non-randomized phase II trial to evaluate hyperbaric oxygen therapy in 21 patients with chronic arm lymphedema and tissue fibrosis following radiotherapy for early breast cancer.
What They Found
At 12 months, 3 out of 19 evaluable patients experienced over a 20% reduction in arm volume, and 6 out of 13 showed over a 25% improvement in lymph clearance rate. Overall, there was a statistically significant but clinically modest mean reduction of 7.51% in ipsilateral arm volume from baseline at 12 months (P = 0.005).
What This Means for Canadian Patients
Canadian patients with chronic arm lymphedema after breast cancer radiotherapy might consider discussing hyperbaric oxygen therapy with their specialists, although the observed benefits were modest. Further research is needed to confirm these findings and determine the optimal role of this therapy in routine clinical practice.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
This was a small, non-randomized phase II trial, limiting the generalizability and definitive conclusions about the efficacy of hyperbaric oxygen therapy.